This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

The effect of souvenaid on functional brain network organisation in patients with mild Alzheimer’s disease: a randomised controlled study

Authors

de Waal, Hanneke, Stam, Cornelis J., Lansbergen, Marieke M., Wieggers, Rico L., Kamphuis, Patrick J. G. H., Scheltens, Philip, Maestú, Fernando, van Straaten, Elisabeth C. W.

Journal

Plos One, Volume: 9, No.: 1, Pages.: e86558-e86558

Year of Publication

2014

Abstract

Background: Synaptic loss is a major hallmark of Alzheimer’s disease (AD). Disturbed organisation of large-scale functional brain networks in AD might reflect synaptic loss and disrupted neuronal communication. The medical food Souvenaid, containing the specific nutrient combination Fortasyn Connect, is designed to enhance synapse formation and function and has been shown to improve memory performance in patients with mild AD in two randomised controlled trials.; Objective: To explore the effect of Souvenaid compared to control product on brain activity-based networks, as a derivative of underlying synaptic function, in patients with mild AD.; Design: A 24-week randomised, controlled, double-blind, parallel-group, multi-country study.; Participants: 179 drug-naïve mild AD patients who participated in the Souvenir II study.; Intervention: Patients were randomised 1∶1 to receive Souvenaid or an iso-caloric control product once daily for 24 weeks.; Outcome: In a secondary analysis of the Souvenir II study, electroencephalography (EEG) brain networks were constructed and graph theory was used to quantify complex brain structure. Local brain network connectivity (normalised clustering coefficient gamma) and global network integration (normalised characteristic path length lambda) were compared between study groups, and related to memory performance.; Results: THE NETWORK MEASURES IN THE BETA BAND WERE SIGNIFICANTLY DIFFERENT BETWEEN GROUPS: they decreased in the control group, but remained relatively unchanged in the active group. No consistent relationship was found between these network measures and memory performance.; Conclusions: The current results suggest that Souvenaid preserves the organisation of brain networks in patients with mild AD within 24 weeks, hypothetically counteracting the progressive network disruption over time in AD. The results strengthen the hypothesis that Souvenaid affects synaptic integrity and function. Secondly, we conclude that advanced EEG analysis, using the mathematical framework of graph theory, is useful and feasible for assessing the effects of interventions.; Trial Registration: Dutch Trial Register NTR1975.;

Bibtex Citation

@article{de_Waal_2014, doi = {10.1371/journal.pone.0086558}, url = {http://dx.doi.org/10.1371/journal.pone.0086558}, year = 2014, month = {jan}, publisher = {Public Library of Science ({PLoS})}, volume = {9}, number = {1}, pages = {e86558}, author = {Hanneke de Waal and Cornelis J. Stam and Marieke M. Lansbergen and Rico L. Wieggers and Patrick J. G. H. Kamphuis and Philip Scheltens and Fernando Maest{'{u}} and Elisabeth C. W. van Straaten}, editor = {Pedro Antonio Valdes-Sosa}, title = {The Effect of Souvenaid on Functional Brain Network Organisation in Patients with Mild Alzheimer's Disease: A Randomised Controlled Study}, journal = {{PLoS} {ONE}} }

Keywords

aged, alzheimer disease, analysis, brain, choline, diet therapy, docosahexaenoic acids, drug effects, eicosapentaenoic acid, electroencephalography, folic acid, food, food formulated, humans, likelihood functions, middle aged, mild cognitive impairment, nerve net, nutritional, phospholipids, regression analysis, selenium, synapses, treatment outcome, uridine monophosphate, vitamins

Countries of Study

Netherlands

Types of Dementia

Alzheimer’s Disease

Types of Study

Randomised Controlled Trial

Type of Outcomes

Cognition

Type of Interventions

Non-pharmacological Treatment

Non-Pharmaceutical Interventions

Other